Soleno Therapeutics, Inc. (SLNO) Q4 2023 Earnings Results

Soleno Therapeutics Misses on EPS, Stock Up 2.16%

This earnings report shows that Soleno Therapeutics continues to face challenges, as indicated by the EPS miss. However, the stock rose by 2.16%, suggesting that investors may be optimistic about the company's future plans and ongoing projects. The lack of revenue data and guidance leaves some uncertainty, but management's comments indicate a focus on long-term goals.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.33	N/A	-6.45%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism about future developments. They are focused on navigating current challenges while working on their strategic objectives.

Management highlighted ongoing efforts to advance their pipeline.

They acknowledged challenges but expressed commitment to long-term goals.

Soleno Therapeutics Misses on EPS, Stock Up 2.16%

Key numbers

Management commentary

Soleno Therapeutics, Inc.

More earnings this week

Soleno Therapeutics Misses on EPS, Stock Up 2.16%

Key numbers

Management commentary